Plné znění - 47/2014 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod - Mezinárodní standard) Mezinárodní úmluvy proti dopingu ve sportu

47/2014 Sb. m. s.

Sdělení

INFORMACE

47

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,

xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Sb. x. x. a x. 46/2008 Xx. m. x. x xxxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 98/2013 Xx. x. x. x Xxxxxxxxxxx úmluvě xxxxx dopingu ve xxxxxx

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 11. listopadu 2013 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX oznámeno schválení xxxxxx znění Xxxxxxx X - Xxxxxxx xxxxxxxxxx látek a xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx.¹⁾

X xxxxx zněním Xxxxxxx X vyslovil xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx podepsal xxxxxxx x xxxxxxx xxxxx Xxxxxxx X Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx X xxxxxxxxx x xxxxxxxx x xxxxxxx x xxxxxxx 34 xxxx. 3 Xxxxxx xxx 1. ledna 2014 x xxxxx xxxx xxxxxxxxx v xxxxxxxx x xxx Xxxxxx xxxxxxxxx. Dnem xxxxxx xxxxxx xxxxx Xxxxxxx I x xxxxxxxx xxxxxxxx platit xxxxx Xxxxxxx I Xxxxxxxxxxx xxxxxx proti xxxxxxx xx sportu xxxxxx xx 1. xxxxx 2013 x xxxxxxxxx xxx č. 98/2013 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx I x její xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.

¹⁾ Xxxxxxxxxxx úmluva proti xxxxxxx ve sportu xxxxxxx xxx 19. xxxxx 2005 x Xxxxxx byla vyhlášena xxx č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

XXXXXXXXXXX XXXXXX XXXXX XXXXXXX VE SPORTU
Příloha X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx
Xxxxx, 1. xxxxx 2014

XXXXXX ZAKÁZANÝCH XXXXX X METOD DOPINGU XXX ROK 2014

XXXXXXX XXXXXXXXXXXXX XXXXX

Xxxxxx od 1. xxxxx 2014

Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx všechny Xxxxxxxx xxxxx budou xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" kromě xxxxx xx xxxxxx S1, X2, S4.4, S4.5 x X6(x) x Xxxxxxxxxx xxxxx M1, X2 x X3.

XXXXX X METODY XXXXXXXX XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)

ZAKÁZANÉ LÁTKY

S0. XXXXXXXXXXX XXXXX

Xxxxxxxxx xxxxxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxx v následujících xxxxxxx Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxx humánní xxxxxxxxxxxx xxxxxxx jakýmkoliv vládním xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. xxxxxx v xxxxxxxxxxxx nebo klinickém xxxxxx xxxxxxx nebo xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, látky xxxxxxxxx xxxxx xxx xxxxxxxxxxx použití), je xxxxxxxx xxxxx.

X1. ANABOLICKÉ XXXXX

Xxxxxxxxxx látky xxxx xxxxxxxx.

1. ANDROGENNÍ ANABOLICKÉ XXXXXXXX (AAS):

(a) Xxxxxxxx* XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3x,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); bolandiol (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx ([1,2]xxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxxxxxxxxxxxxxxxx (17α-methyl-5α-androst-2-en-17β-ol); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-xxxxxx-4-xx-17α-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17β-xx); xxxxxxxxx; 4-hydroxytestosteron (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx); methyldienolon (17β-hydroxy-17α-methylestra-4,9-dien-3-on); xxxxxx-1-xxxxxxxxxxx (17β-hydroxy-17α-methyl-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); methyltestosteron; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (estr-4-en-3,17-dion); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; prostanozol (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1'X-xxxxxxxx[3,4,:2,3]-5α-xxxxxxxxxx); xxxxxxxxx; stanozolol; xxxxxxxxx; 1-xxxxxxxxxxx (17β-hydroxy-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx (17β-xxxxxxxxxx-4,9,11-xxxxx-3-xx) x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx.

(x) Endogenní** XXX, pokud xxxx xxxxxx exogenně:

Androstendiol (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX), 3β-xxxxxxxxxxxxx-5-xx-17-xx), testosteron a xxxxxx xxxxxxxxxx x xxxxxxx, xxx ne x xxxxxxxx pouze xx xx:

5α-xxxxxxxxx-3α,17α-xxxx	5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)
5α-xxxxxxxxx-3α,17β-xxxx	xxx-xxxxxxxxxxxxxxxxxx
5α-xxxxxxxxx-3β,17α-xxxx	xxxxxxxxxxxxxx
5α-xxxxxxxxx-3β,17β-xxxx	xxxxxxxxxxxxxx
xxxxxxx-4-xx-3α,17α-xxxx	3α-xxxxxxx-5αxxxxxxxxx-17-xx
xxxxxxx-4-xx-3α,17β-xxxx	3β-xxxxxxx-5αxxxxxxxxx-17-xx
xxxxxxx-5-xx-3β,17α-xxxx	7α-xxxxxxx-XXXX
xxxxxxx-5-xx-3α,17α-xxxx	7β-xxxxxxx-XXXX
xxxxxxx-5-xx-3α,17β-xxxX	7-xxxx-XXXX
xxxxxxx-5-xx-3β,17α-xxxx	19-xxxxxxxxxxxxxx
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)	19-xxxxxxxxxxxxxxxxx

Xxx xxxxx xxxxxxx xxxx xxxxx:

* "xxxxxxxx" xx xxxxxxxx k xxxxx, xxxxxx xxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxx.

** "xxxxxxxxx " xx xxxxxxxx k xxxxx, xxxxxx tělo xxxxxxxx xxxxxxxxx xxxxxxxxx.

2. Xxxxxxx xxxxxxxxxx látky, zahrnující:

Klenbuterol, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), tibolon, xxxxxxx, xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx na xx.

X2. XXXXXXXXX XXXXXXX, RŮSTOVÉ XXXXXXX A PŘÍBUZNÉ XXXXX

Xxxxxxxxxxx látky x xxxxx látky s xxxxxxxx xxxxxxxxx strukturou xxxx podobnými biologickými xxxxxx xxxx xxxxxxxx:

1. Xxxxx stimulující xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (EPO), xxxxxxxxxxx (dEPO), stabilizátory xxxxxxx vyvolávajícího xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), xxxxxxxxxxx /Hematide/);

2. Xxxxxxxxxxxxxxxxxx (CG) a Xxxxxxxxxxxx hormon (XX) x jejich xxxxxxxxxx xxxxxxx u xxxx;

3. Xxxxxxxxxxxxxx a xxxxxx xxxxxxxxxx xxxxxxx;

4. Xxxxxxx xxxxxx (XX) x xxxx uvolňující xxxxxxx x xxxxxxxx podobný xxxxxxx xxxxxx-1 (XXX-1).

Xxxxx xxxx xxxx xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxx:

Xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXXx), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), xxxxxxxxxx xxxxxxx xxxxxxx (XXX), xxxxxxx xxxxxx odvozený z xxxxxxxx xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX), xxxxxx xxxx xxxxxxxxx jiné xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx xxxx degradaci xxxxxxxx xxxxx, šlach x xxxxxx, krevní xxxxxxxx, využití xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx;

x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X3. XXXX2- XXXXXXXX

Xxxxxxx xxxx-2 xxxxxxxx, xxxxxx xxxxx xxxxxxxxxx xxxxxxxxx isomerů (např. x- x x-), xxxx xxxxxxxx xxxxx xxxxxxxxxxx salbutamolu (xxxxxxxxx 1600 mikrogramů za 24 xxxxx), xxxxxxxxxxxx xxxxxxxxxxx (xxxxxxxxx xxxxxx xxxxx 54 mikrogramů xx 24 xxxxx) x xxxxxxxxxxx, pokud xxxx xxxxxx x xxxxxxxx x xxxxxxx x doporučeným xxxxxxxx xxxxxxx xxxxxxx.

Xxxxxxxxxx xxxxxxxxxxx x moči x xxxxxxxxxxx xxxxx xxx 1000 xx/xx a xxxxxxxxxx xxxxxxxxxxx v xxxx v xxxxxxxxxxx xxxxx než 40 xx/xx xxxxxx xxxxxxxxxx xx xxxxxxxxx terapeutické xxxxxxx, xxx xxxx xxxxxxxxxx xx pozitivní xxxxxxxxxxx nález, pokud xxxxxxxxx xxxxxxxxx kontrolovanou xxxxxxxxxxxxxxxxx studií, xx xxxxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx xxxxx xxx xxxx xxxxxxx xxxxxxx.

X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxxx aromatáz, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx, xxxxxxxxxx, androsta-1,4,6-trien-3-17-dion (xxxxxxxxxxxxxxxxx), 4-androsten-3,6,17-trion (6-xxx), xxxxxxxxx, xxxxxxxxx, letrozol, xxxxxxxxxxx, xxx xx x xxxxxxxx pouze xx ně.

2. Selektivní xxxxxxxxxx estrogenových xxxxxxxxx (XXXX), zahrnující:

Raloxifen, xxxxxxxxx, xxxxxxxxx, ale xx x xxxxxxxx pouze xx xx.

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx zahrnující:

Cyklofenil, xxxxxxxxxxx, xxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.

4. Xxxxx xxxxxxxxxxxx funkce xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, xxx xx x omezením pouze xx xx.

5. Xxxxxxxxxxx xxxxxxxxxx:

x) Insuliny;

b) Receptor xxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Peroxisome Proliferator Xxxxxxxxx Xxxxxxxx δ (XXXXδ) xxxxxxxx/ (xxxx. XX 1516) a Xxxxxxxx xxxxxxxxxxxxxxx xxx xxxxxxxxxx AMP v xxxxxxxxxxx x PPAR xxxxx /PPARδ-AMP-activated xxxxxxx xxxxxx (AMPK) xxxx xxxxxxxx/ (xxxx. XXXXX)

X5. XXXXXXXXX X XXXXXXX XXXXXXXXX XXXXX

Xxxxxxxxx xxxxx xxxx xxxxxxxx. Xxxxxxxx:

Xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx (např. xxxxxxxx, xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, hydroxyethylškrobu x xxxxxxxxx), xxxxxxxxxx x další xxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx. Lokální xxxxxx xxxxxxxxxxxx xxx zubní xxxxxxxx xxxx xxxxxxxx.

Xxxxxxxxx xxxxxxxx:

Xxxxxxxxxxxx, amilorid, xxxxxxxxx, xxxxxxxxx, chlortalidon, indapamid, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, spironolakton, thiazidy (xxxx. xxxxxxxxxxxxxxxxxx, hydrochlorothiazid, xxxxxxxxxxxxx), triamteren, vaptany (xxxx. xxxxxxxxx) x xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx (kromě drospirenonu, xxxxxxxxx a xxxxxxxxx xxxxxx dorzolamidu x xxxxxxxxxxxx, které xxxxxx xxxxxxxx).

Xxx použití (Při Xxxxxxx, xxxxxxxx Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx xxxxx se xxxxxxxxxx xxxxxxxx xxxxxxx (tj. xxxxxxxxxx, xxxxxxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) ve xxxxxxx x xxxxxxxxxx xxxx xxxxx maskovací látkou xx vyžadováno udělení xxxxxxxxxx Terapeutické xxxxxxx xx tuto xxxxx xxxxx x xx, xxxxx xxx xxxx xxxxxxx na xxxxxxxxxx xxxx jinou maskovací xxxxx.

XXXXXXXX METODY

M1. MANIPULACE X XXXX X XXXXXXXX KOMPONENTAMI

Zakázané je xxxxxxxxxxx:

1. Xxxxxx nebo xxxxxxxxxxxxx xxxxxxxxxxx množství xxxxxxxxx, xxxxxxxx (xxxxxxxxx) xxxx heterologní xxxx xxxx xxxxxxxxx xxxxxxx x jim xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx systému.

2. Xxxxx zvyšování spotřeby, xxxxxxx xxxx dodávky xxxxxxx, xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (např. xxxxxx náhražky založené xx xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), perfluorochemikálie a xxxxxxxxxxx (RSR13), xxx xx x xxxxxxxx xxxxx xx ně. Xxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxx.

3. Xxxxxxxxx forma xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx s xxxxxxxx komponentami xxxxxxxxxxx xxxx chemickými způsoby.

M2. XXXXXXXX A XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxx, xxxx pokus x xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx při Dopingové xxxxxxxx. Xx xxxxxxxx xxxxxx x/xxxx úpravu (xxxx. proteázami) moči, xxx ne s xxxxxxxx pouze xx xx.

2. Xxxxxxxxxx infuze x/xxxx xxxxxxx xxxx xxx 50 xx xx 6 xxxxx xxxxx infuzí xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxx nebo xxxxxxxxxx xxxxxxxxxxxxx xxxxx.

X3. XXXXXX XXXXXX

X xxxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:

1. Xxxxxxxx xxxxxxxx nukleových xxxxxxx xxxx xxxxxx xxxxxxx;

2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx modifikovaných xxxxx.

XXXXX X XXXXXX XXXXXXXX XXX SOUTĚŽI

Kromě kategorií X0 xx X5 x X1 až X3 uvedených xxxx xxxx Při Xxxxxxx xxxxxxxx x následující xxxxxxx:

XXXXXXXX LÁTKY

S6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx včetně xxxxx xxxxxx xxxxxxxxxx optických xxxxxxx (xxxx. x- x l-) jsou xxxxxxxx, s výjimkou xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx místního xxxxxxx x stimulancií xxxxxxxxxx do Monitorovacího xxxxxxxx pro rok 2014*.

Xxxxxxxxxxx xxxxxxxx:

(x) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, fendimetrazin, xxxxxxxxx, fenfluramin, fenkamin, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx /4-xxxxxxxxxxxxxx (xxxxxxxx)/, xxxxxxxxxx, klobenzorex, kokain, xxxxxxxxxxx, xxxxxxxxxx, mefenorex, xxxxxxxxxxx, xxxxxxxxxxxx (d-), xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, prenylamin, xxxxxxxxx.

Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxx x xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxxx xxxxxxxxxxx (xxxxxxxx):

Xxxxxxxxx (epinefrin)****, xxxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxx***, xxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, famprofazon, xxxxxxxxxxx, fenkamfamin, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxx), xxxxxxxxxxxx, katin**, xxxxxxx x xxxx analoga (xxxx. mefedron, xxxxxxxxx, xxxx-xxxxxxxxxxxxxxxxxxxxx), xxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx***, metylendioxymetamfetamin, xxxxxxxxxxxx, xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, oxilofrin (xxxxxxxxxxxxx), xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, tenamfetamin (xxxxxxxxxxxxxxxxxxxxx), trimetazidin, tuaminoheptan x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky.

* Následující xxxxx zahrnuté xx Xxxxxxxxxxxxxx xxxxxxxx 2014 (xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, nikotin, xxxxxxxxx, xxxxxxxx) xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.

** Xxxxx je xxxxxxxx xxxxx xxx koncentraci xxxxx xxx 5 xxxxxxxxxx v 1 xx moči.

*** Xxxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxx při xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx xxxx.

**** Lokální xxxxxx xxxxxxxxxx (epinefrinu) (xxxx. xxxxx, xxxx xxxxxxxx) nebo xxxx xxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.

***** Xxxxxxxxxxxxx xx xxxxxxx, xxxxx xxxx xxxxxxxxxxx x moči xx xxxxx xxx 150 mikrogramů xx xxxxxxxx.

X7. NARKOTIKA

Zakázané je xxxxxxxxxxx:

Xxxxxxxxxxx, dextromoramid, diamorfin(heroin), xxxxxxxx x xxxx xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, oxykodon, oxymorfon, xxxxxxxxxx, xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxx (xxxx. hašiš, xxxxxx x xxxxxxxxx) xxxx xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (THC) x kanabimimetika (např. "Xxxxx", JWH018, XXX073 x XX-210) xxxx xxxxxxxx.

X9. XXXXXXXXXXXXXXXXXXXX

Xxxxxxx glukokortikosteroidy xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx nitrosvalovou xxxxxxxx xxxx xxxxxxxx.

XXXXX XXXXXXXX V URČITÝCH XXXXXXXX

X1. XXXXXXX

Xxxxxxx (xxxxxx) xx zakázaný xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx bude provádět xxxxxxxx zkouškou x/xxxx xxxxxxxx krve. Xxxxxxx xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx xx xxxxxxxxxxxx koncentrací xxxxxxxx x xxxx 0.10 x/x.

• Automobilový xxxxx (XXX)

• Karate (WKF)

• Xxxxxxx xxxxxx x xxxxxxxxxxxx (XXX)

• Lukostřelba (XX)

• Motocyklový sport (XXX)

• Xxxxx xxxxxxxxxx (XXX)

X2. XXXX-XXXXXXXXX

Xxxxx není xxxxx určeno, xxxx-xxxxxxxxx xxxx zakázány pouze Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx.

• Xxxxxxxxxxxx xxxxx (XXX)

• Billiard (xxxxxxx xxxxxxxxxx) (XXXX)

• Xxxx (XXX)

• Xxxxxxxxxxx (XX) (xxxxxxxx xxxx Xxxx soutěž)

• Lyžování (XXX) - skoky xx lyžích a xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx, x xxxxxxxxx X-xxxxx x "big xxx"

• Xxxxxxx (XXXX, XXX) (xxxxxxxx xxxx Xxxx soutěž)

• Šipky (XXX)

Xxxx-xxxxxxxxx zahrnují xxxxxxxxxxx xxxxx:

Xxxxxxxxxx, alprenolol, atenolol, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, timolol, ale xx s xxxxxxxx xxxxx xx xx.

Informace

Právní xxxxxxx x. 47/2014 Xx. m. x. xxxxx účinnosti xxxx 20.9.2014.

Xxxxxx předpis x. 47/2014 Xx. x. x. xxx xxxxxx právním předpisem č. 19/2017 Sb. m. s. x xxxxxxxxx xx 6.4.2017.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx jiných xxxxxxxx předpisů x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx se xxxx xxxxxx derogační xxxxx xxxxx xxxxxxxxx právního xxxxxxxx.